Optum Pharmacy 801, Inc.

Optum Pharmacy 801, Inc. (doing business as Avella Of Deer Valley, Inc #038) is a 503A certified specialty pharmacy subsidiary of UnitedHealth Group Incorporated that delivers pharmaceutical compounding services—specifically chemotherapy preparation, hazardous sterile drug formulations, and customized intravenous solutions—to the Department of Veterans Affairs as a prime contractor operating under full-and-open, non-set-aside competition. The company is headquartered in Phoenix, Arizona, and operates compounding facilities in Arizona and at regional VA medical centers, performing all work to United States Pharmacopeia standards USP 797 and 800 using aseptic techniques and closed-system transfer devices.

Optum Pharmacy 801 operates exclusively as a prime contractor; all 112 awards in the source data are prime contracts or IDVs with zero subcontractor engagement. The vendor's recent activity has accelerated sharply—from nine awards in 2022 to 26 in 2024—with 23 awards issued in 2025 before the source snapshot on March 1, 2026, yielding a combined potential value across all awards of $101.2 million against which $37.8 million has been obligated (37% utilization). The customer base is entirely the Department of Veterans Affairs, concentrated across five VISNs. By award count, the top customers are VISN 2 (30 awards, $13.2 million combined potential value), VISN 16 (15 awards, $8.8 million), VISN 21 (15 awards, $12.5 million), VISN 22 (15 awards, $21 million), and VISN 17 (12 awards, $24.3 million). By dollar magnitude, VISN 17 dominates at $24.3 million potential value across 12 awards, followed by VISN 22 at $21 million across 15 awards—a reversal from the count-based ranking that signals larger average order values in those two networks. These five VISNs account for 78% of total awards and 79% of combined potential value.

The vendor holds named positions on multiple single-award BPAs and IDCs with individual VISNs. Representative named vehicles include a $4.3 million multiple-award BPA with VISN 15 for hazardous pharmacy compounding services (awarded December 1, 2023, through May 31, 2026); a $4.135 million single-award IDC with VISN 10 for hazardous chemotherapy compounding (May 1, 2024 to April 30, 2026); a $4 million single-award IDC with VISN 21 for contingency hazardous pharmaceutical compounding services in Reno, Nevada (May 1, 2024 to September 30, 2028); a $2.75 million single-award IDC with VISN 21 for hazardous pharmaceutical compounds in Las Vegas (February 1, 2024 to September 30, 2026); and a $2.623 million single-award BPA with VISN 2 for chemotherapy compounding (November 17, 2021 to November 16, 2026). The top five named parent vehicles by task order count are the VISN 17 Pharmacy Compounding IDC (7 task orders, $8.5 million), the VISN 15 Hazardous Pharmacy Compounding BPA (9 task orders, $1.9 million), and three smaller vehicles carrying 5 task orders each with combined values ranging from $146 thousand to $597 thousand.

Representative recent prime awards include a $2.5 million single-award IDC with VISN 5 (effective June 30, 2025) for custom-dosed chemotherapy IV medications for the Baltimore VA Medical Center; a $1.35 million delivery order with VISN 16 (October 1, 2024) for hazardous compounding services in Biloxi, Mississippi running through September 30, 2029; a $1.104 million delivery order with VISN 17 (June 1, 2025) for pharmacy compounding services supporting the Dallas and Amarillo VA Medical Centers; a $667 thousand delivery order with VISN 2 (December 11, 2023) for chemo compounding services; a $500 thousand delivery order with VISN 20 (June 30, 2025) for contingency outsourcing of compounded chemotherapy medications in the Portland area; and a $441 thousand delivery order with VISN 21 (October 1, 2025) for contingency hazardous pharmaceutical compounding in Reno. Award types span purchase orders, delivery orders against IDCs and BPAs, and BPA calls, with ceiling values ranging from hundreds of dollars (likely adjustments or amendments) to multimillion-dollar vehicle ceilings.

Activity shows sustained competition across all 112 awards with no set-aside designations. Within the next 24 months, 15 awards with a combined potential value of $4.7 million face ultimate completion dates and therefore recompete risk. The vendor's category concentration is tight: 103 awards fall under NAICS 325412 (Pharmaceutical Preparation Manufacturing), with 66 awards carrying PSC 6505 (Drugs and Biologicals) and 37 carrying PSC Q517 (Pharmacy Services). SCI-reported invoicing for the federal service contracts subset was $501 thousand across FY2023–FY2024 (FY2023: $386 thousand at 0.5 FTEs; FY2024: $115 thousand at 0.2 FTEs), indicating minimal professional-services labor intensity and a goods-and-compounding-delivery business model. Median government-paid hourly rates on SCI-reportable contracts ran $307.95/hr, with rates ranging from $188.42/hr to $383.99/hr across the 10th and 90th percentiles. The vendor operates as a subsidiary of UnitedHealth Group Incorporated, a large diversified healthcare contractor that also holds a $3.3 billion Medical Disability Examination IDIQ and a multi-billion-dollar OASIS+ contract with GSA.